On April 24, 2025 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that it has been selected to present at the upcoming 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois and online (Press release, Genprex, APR 24, 2025, View Source [SID1234652103]). Genprex’s abstract was selected for a poster presentation for the Trials in Progress portion of the conference. The Company will present the trial design of the Acclaim-3 Phase 1/2 clinical trial evaluating Genprex’s lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), in combination with Tecentriq as maintenance therapy for the treatment of extensive stage small cell lung cancer (ES-SCLC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very excited to be selected to present the design of our Acclaim-3 clinical trial at this year’s annual ASCO (Free ASCO Whitepaper) meeting, among some of the most cutting-edge advances in oncology," said Ryan Confer, President and Chief Executive Officer at Genprex. "We look forward to presenting the trial design of Acclaim-3 to other organizations and industry leaders committed to shaping the future of cancer care."
The featured Genprex abstract to be presented at the 2025 ASCO (Free ASCO Whitepaper) Annual Meeting:
Title: A phase 1/2 clinical trial of quaratusugene ozeplasmid gene therapy and atezolizumab maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC)
Session Type: Poster Session
Presentation Date: Saturday, May 31, 2025
Presentation Time: 1:30 – 4:30 p.m. CT
Presenter: Bo Wang, MD, Oncology Associates of Oregon